High induction dosing of risankizumab in patients with moderate-to-severe plaque psoriasis: Interim results from the phase 2 KNOCKOUT study

被引：0

作者：

Blauvelt, A. ^{[1
]}

Gudjonsson, J. ^{[2
]}

Matheson, R. ^{[1
]}

Liu, R. ^{[3
]}

Shi, L. ^{[3
]}

Photowala, H. ^{[3
]}

Ehst, B. ^{[1
]}

机构：

[1] Oregon Med Res Ctr, Portland, OR USA

[2] Univ Michigan, Dept Dermatol, Sch Med, Ann Arbor, MI USA

[3] AbbVie Inc, N Chicago, IL USA

来源：

JOURNAL OF INVESTIGATIVE DERMATOLOGY | 2023年 / 143卷 / 09期

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

LB1703

引用

页码：B16 / B16

页数：1

共 50 条

[31] Risankizumab in Japanese patients with moderate-to-severe palmoplantar pustulosis: Results from the randomized, phase 3 JumPPP study
Okubo, Yukari
Murakami, Masamoto
Kobayashi, Satomi
Tsuji, Shigeyoshi
Kishimoto, Mitsumasa
Ikeda, Kimitoshi
Jibiki, Maiko
Neimark, Ezequiel
Padilla, Byron
Shen, Jie
Peters, Sydney
Terui, Tadashi
JOURNAL OF DERMATOLOGY, 2025, 52 (04): : 593 - 602
[32] The Effectiveness of Risankizumab Following Guselkumab Failure in Moderate-to-Severe Psoriasis Patients: A Retrospective Study
Hamm, Camille
Ramsoondar, Nusha
McGillis, Michaela
Waugh, Miranda
Gooderham, Melinda
Giroux, Lyne L.
JOURNAL OF CUTANEOUS MEDICINE AND SURGERY, 2023, 27 (05) : 476 - 480
[33] Efficacy of Risankizumab compared with placebo across subgroups in patients with moderate-to-severe plaque psoriasis: integrated analyses from three phase 3 trials
Lebwohl, M.
Ghislain, P.
Kerdel, F.
Gu, Y.
Valdes, J. M.
Thompson, E. H.
Lynde, C.
EXPERIMENTAL DERMATOLOGY, 2019, 28 (03) : E25 - E25
[34] Efficacy of Risankizumab compared with placebo across subgroups in patients with moderate-to-severe plaque psoriasis: integrated analyses from three phase 3 trials
Lebwohl, M.
Ghislain, P-D
Kerdel, F.
Gu, Y.
Valdes, J.
Thompson, E. H.
Lynde, C.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2019, 17 : 115 - 116
[35] Pharmacogenetics of ustekinumab in patients with moderate-to-severe plaque psoriasis
Prieto-Perez, Rocio
Llamas-Velasco, Mar
Cabaleiro, Teresa
Solano-Lopez, Guillermo
Marquez, Beatriz
Roman, Manuel
Ochoa, Dolores
Talegon, Maria
Dauden, Esteban
Abad-Santos, Francisco
PHARMACOGENOMICS, 2017, 18 (02) : 157 - 164
[36] Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study
Crowley, Jeffrey J.
Langley, Richard G.
Gordon, Kenneth B.
Pinter, Andreas
Ferris, Laura K.
Rubant, Simone
Photowala, Huzefa
Xue, Zhenyi
Wu, Tianshuang
Zhan, Tianyu
Beeck, Stefan
Shah, Megha
Warren, Richard B.
DERMATOLOGY AND THERAPY, 2022, 12 (02) : 561 - 575
[37] Pharmacogenetics of ustekinumab in patients with moderate-to-severe plaque psoriasis
Dauden, E.
Prieto-Perez, R.
Llamas-Velasco, M.
Cabaleiro, T.
Abad-Santos, F.
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2016, 136 (09) : S188 - S188
[38] Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study
Jeffrey J. Crowley
Richard G. Langley
Kenneth B. Gordon
Andreas Pinter
Laura K. Ferris
Simone Rubant
Huzefa Photowala
Zhenyi Xue
Tianshuang Wu
Tianyu Zhan
Stefan Beeck
Megha Shah
Richard B. Warren
Dermatology and Therapy, 2022, 12 : 561 - 575
[39] High induction dosing of risankizumab in patients with moderate-to-severe plaque leads to marked suppression of resident memory T cell number and function in resolved psoriatic skin
Blauvelt, Andrew
Jiang, Rundong
Ehst, Benjamin
Matheson, Robert
Tosi, Lam C.
Bogle, Rachael
Fox, Jennifer
Gharaee-Kermani, Mehrnaz
Billi, Allison C.
Shi, Linyu
Photowala, Huzefa
Gudjonsson, Johann
BRITISH JOURNAL OF DERMATOLOGY, 2024, 191
[40] Effectiveness of guselkumab in patients with moderate-to-severe plaque psoriasis: a retrospective study from China
Huang, He
Liu, Hao
Zhu, Zhengwei
Wang, Wenjun
Liang, Bo
Tang, Huayang
Yang, Sen
Sheng, Yujun
Sun, Liangdan
Zhang, Xuejun
EUROPEAN JOURNAL OF DERMATOLOGY, 2024, 34 (01) : 73 - 78

← 1 2 3 4 5 →